RU2554748C2 - Agent for treatment of enteritis in animals - Google Patents

Abstract

FIELD: veterinary medicine.

SUBSTANCE: agent comprises enrofloxacin and excipients. The agent additionally comprises humates of peat or sapropel, with the following ratio of the components, wt %: enrofloxacin substance - 0.5; alkaline solution of humates (pH=12-13) - 80; succinic acid - to pH 10-11; propylene glycol - the rest. The agent is administered with the liquid feed once a day for three to five days at a dose of from 0.5 to 1.0 ml per 1 kg of body weight.

EFFECT: manifestation of pronounced therapeutic effect.

5 tbl, 2 ex

Description

The invention relates to agriculture, in particular to veterinary medicine and can be used in animal husbandry as a feed additive for treatment of digestive disorders in animals and birds.

Known antibacterial agent from the group of fluoroquinolones - enrofloxacin, used in the treatment of animals with bacterial infections, for internal (by mouth) and injection use.

A disadvantage of the known means is the absence of a nonspecific stimulating (tonic) action of the animal organism and the presence of a negative effect, which is manifested in a violation of the development of cartilage in young animals. When using enrofloxacin, the simultaneous use of non-steroidal anti-inflammatory drugs, macrolides and tetracyclines is strictly prohibited. A contraindication for the use of the drug is also the detection of strains of pathogenic bacteria resistant to enrofloxacin.

Closest to the claimed agent for the treatment of bacterial enteritis (colibacteriosis, salmonellosis, necrotic enteritis and others) in animals are preparations for oral (internal) administration in a dose of 2.5-5 mg / kg of the active substance, 1 time per day, 3- 5 days: “Enroflon®-10% oral solution” containing 100 ml of enrofloxacin in 1 ml and excipients: potassium hydroxide, benzyl alcohol, water, manufacturer: LLC “VIK - animal health”, Russia, registration number PVR- 2-2.9 / 00089 (cited: Medicines wa for veterinary use in Russia. - Reference "Vidal Specialist." - M.: AstraFarmService. - 2013. - S.360-361); Enroflox in 1 ml of 100 mg enrofloxacin and excipients: potassium hydroxide, benzyl alcohol, purified water, manufacturer INVESA, Spain, registration number PVI-2-3.5 / 00438 dated 02.24.11 (cited: Medicines for veterinary use in Russia. - Reference "Vidal Veterinarian." - M.: AstraFarmService. - 2011. - S.419-420). All of these analogues are summarized by the similarity in the fact that their solvents have a high alkalinity index (pH = 9.5-11.5). Other sources - “Injection or infusion solution of enrofloxacin” (RF patent No. 214722, application submission: 12/28/1995) and “Treatment of mastitis with enrofloxacin” (RF patent No. 2413514, application submission 10/28/2005), mainly acidic forms of complex solvents.

Known means for the prevention of animal diseases by increasing non-specific resistance and accelerating growth under the general name "humates" obtained from natural organic raw materials (coal, peat, sapropel) by alkaline hydrolysis, used as a feed additive that does not have antibacterial properties.

Closer to the claimed agent is Guvitan, a liquid product of alkaline hydrolysis of peat containing humic substances, used as a feed additive to animals to increase their resistance to diseases, by activating digestion processes, normalizing metabolism, and binding toxins in the gastrointestinal tract ( TU 9283-00256462103-2010. Producer LLC "Russ", Voronezh, 394088, PO Box 97). A known method for the preparation and use of a humate-containing product (alkaline hydrolyzate of sapropel) for calf anemia in combination with transcranial electrical stimulation (RF No. 2392945, application: 2008130210/13, 07/21/2008).

The disadvantage of Guvitan and the alkaline hydrolyzate of sapropel is the complete absence or presence of a weak antibacterial effect on the pathogenic microflora that cause enteritis.

However, each of the above funds is used separately for animals, and their joint role in the treatment of animals with bacterial enteritis has not been determined.

The aim of the invention is the creation of a new tool for the treatment of bacterial enteritis in animals, which has an antimicrobial and nonspecific stimulating effect and provides a reduction in animal death, disease severity and treatment time (not less than 10%).

The technical result is a tool that provides improved results of treatment of animals with enteritis, expressed in reducing the duration and severity of the disease, reducing the number of relapses and the amount of prevented damage from the disposal of animals.

The technical result is achieved by the combined manifestation of mutually enhanced healing properties of the components of the product and the mutual elimination of the disadvantages of each component, which cannot be achieved with the separate use of each component.

Distinctive features are that in order to achieve the best therapeutic effect of internal (oral) use with liquid feed of enrofloxacin in enteritis in animals, it is previously dissolved in an alkaline solution of humates.

The essence of the proposed tool is that the manufacture of the product is carried out by obtaining a solution of the antibacterial component of enrofloxacin (from 0.2 to 1.0 wt.% In an alkaline solution of humic substances (from 0.1 to 0.5 wt.%) Sapropel (peat The preference for alkaline solutions is due to the fact that enteritis is recorded mainly in young animals (except for enterotoxemia of piglets), in the diet of which lactose, easily fermentable to lactate (lactic acid), is present in the form of "acidic catarrhal intestines a. ”To ensure optimal pH, bases (NaOH, KOH) and acid (succinic acid) are used, propylene glycol (1,2-propanediol) is used to prevent crystallization of the solution. In addition, succinic acid in the form of salts (succinates) and propylene glycol (diatomic alcohol) provide buffering of the medium in the gastrointestinal tract, and when absorbed, they contribute to the normalization of energy metabolism, participating in the cycle (metabolism) of tricarboxylic acids, thereby preventing the development of metabolic acidosis. The combination of the listed properties of the proposed tool provides an increase in therapeutic efficacy as a result of the simultaneous complex effect of the components of the tool on the body of a sick animal and on the pathogen, which is manifested in accelerating the recovery of animal health and weakening the possible side effects of enrofloxacin. At the same time, production costs are reduced: instead of producing two separate alkaline solutions of enrofloxacin and humates, a simplified technology for producing one agent is proposed by dissolving the powder of the substance enrofloxacin in an alkaline solution (pH = 12-13) of humates, followed by the introduction of succinic acid into the solution until pH = 10- 11 and the addition of propylene glycol to wt.% 10-30.

Examples of obtaining funds for the treatment of bacterial enteritis in animals:

Table 1 Example 1 Name of components Permissible limits Medication Recipe BUT Enrofloxacin substance, wt.% 0.2-1.0 0.5 B The solution of humates, wt.% 70-90 80 - humic substances, wt.% 0.1-0.5 0.3 - sodium hydroxide (or potassium hydroxide) up to pH = 12-13 - succinic acid until pH = 10-11 AT Propylene glycol, wt.% 10-30 rest

table 2 Example 2 Name of components Permissible limits Medication Recipe BUT Enrofloxacin substance, wt.% 0.2-1.0 0.5 B Guvitan TU 9283-00256462103-2010. 70-90 80 AT Sodium hydroxide (or potassium hydroxide) up to pH = 12-13 G succinic acid until pH = 10-11 D Propylene glycol, wt.% 10-30 rest

Table 3 Example 3 Name of components Permissible limits Medication Recipe BUT Enrofloxacin substance, wt.% 0.2-1.0 0.5 B Sapropel alkaline hydrolyzate with pH = 12-13, wt.% (RF patent No. 2392945) 70-90 80 AT succinic acid until pH = 10-11 G Propylene glycol, wt.% 10-30 rest

Clinical researches:

Example 1

The experience of studying the therapeutic efficacy of the proposed drug in comparison with the well-known "Enroflon®-10% oral solution" and "Guvitan" was carried out on calves with a diagnosis of acute digestive upset of a bacterial nature (enteritis of bacterial etiology) from the age of 2-3 days to 1 month at dairy farms of the Omsk and Tyumen regions. In the experimental group, the drug was given to the calves individually orally in a mixture with milk (colostrum) when feeding once a day at a dose of 1.0 ml per 1 kg of body weight, while the daily dose of the active substance enrofloxacin was 5 mg / kg of calf body weight. In the 1st control group, calves were treated with Enroflon once a day with liquid feed at a daily dose of 5 mg / kg body weight. In the 2nd control group "Guvitan" the calves were injected with liquid feed at 0.8 ml per kg of body weight 1 time per day.

Analysis of the test results (table 4) indicates the best therapeutic efficacy of the developed tool. Thus, in the experiment, a 100% therapeutic effect was obtained from the use of the proposed drug, and in the control groups where Enroflon and Guvitan were used respectively, the effectiveness was lower and amounted to 97% and 56%, respectively. In addition, in the experimental group, recovery (on the basis of the disappearance of the main symptom of the disease - diarrhea) occurred earlier by 34%, and there were no animal deaths and relapses of the disease. The data obtained indicate that the proposed remedy for therapeutic action is superior to Enroflon and Guvitan.

Table 4 The comparative effectiveness of treatment for bacterial enteritis of calves with the proposed tool in comparison with Enroflon and Guvitan Calf Treatment Performance Indicators Groups of animals Experience Control 1 Control 2 Means Enroflon Guwitan The number of animals in the group, goals 47 34 eighteen The number of spent doses of the tested funds for 1 calf and / total per group 5 (235) 5 (170) 5 (90) The main symptom of the disease (diarrhea) disappeared on average by 1 calf, days 2,53 3.41 - The disappearance of the main symptom of the disease (diarrhea) in calves, goals /%: - on the second day, goals / (%) 21/45 9/27 0 - on the third day (with an increasing number), goals /% 39/83 17/50 5/27 - on the fourth day, goals / (%) 45/96 28/82 12/67 - on the fifth day, goals / (%) 47/100 34/100 15/83 Remained sick calves, goal. /% 0 0 3/17 The number of dead animals, goals /% 0 0 1/6 The number of relapses of the disease, cases /% 0 one 4/22 Therapeutic efficacy,% one hundred 97 56

Example 2

The second experiment on establishing the effectiveness of preventive therapy (drug prophylaxis) with the proposed remedy for mass diseases of newborn calves was carried out in comparison with Enroflon and Guvitan preparations, and statistical data on the incidence and death of calves that were not given preventive therapy were taken as a general control , and the causes of the disease were the same in all groups: high bacterial contamination of animals with pathogenic bacteria from the group of Escherichia coli. The test means were given to the calves inside with liquid food (milk, colostrum) once a day in the morning drink for 5 days, starting from the first feeding, in doses, based on ml / kg of body weight: means - 1; Enroflon - 0.05 and Guwitan - 0.8.

The effectiveness of preventive therapy (table 5) in the experiment and in the two control groups was 96%, 93%, and 35%, respectively, and the reduction rate in the incidence of animals was 11, 6, and 2 times in the groups, respectively. The results obtained indicate that the use of the proposed tool has a pronounced preventive effect in bacterial enteritis of calves and is superior in efficiency to Enroflon and Guvitan. ”

Table 5 Preventive therapy (drug prevention) for massive bacterial enteritis in newborn calves (with incidence of enteritis in the first 10 days of life - 45% of the number of births) Calf Prevention Therapy Groups of animals Experience Control 1 Control 2 General control Means Enroflon Guwitan No preventative therapy The number of animals in the group, goals 120 57 31 60 The number of spent doses of the tested funds for 1 calf and / total per group 5 (600) 5 (285) 5 (155) 0 Calves got sick within 10 days, goal. 5 four 6 27 The incidence of calves in the first 10 days of life, goals per 100 calves four 7 19 45 Calves fell, goal 0 0 one four The rate of decrease in incidence, times eleven 6 2 - Preventive effect on 100 calves, goal. 96 93 35 0

Analysis of the results of clinical trials of the proposed funds for the treatment of piglets, chickens and rabbits, patients with bacterial enteritis, also showed good therapeutic efficacy. No other types of tests were performed on animals.

Thus, the use of the proposed tool for the treatment of bacterial enteritis in young farm animals (calves, pigs, chickens, rabbits) has a more pronounced therapeutic effect in comparison with the prototypes "Enroflon and Guwitan."

The tool is easy to use and effective. Its production does not require large expenditures.

Claims (1)

An agent for treating bacterial enteritis in animals, for internal administration with liquid food once a day for three to five days at a dose of 0.5 to 1.0 ml per 1 kg of body weight, containing enrofloxacin and excipients, characterized in which additionally contains humates of peat or sapropel, in the following ratio of components, wt.%: enrofloxacin substance - 0.5; alkaline solution of humates (pH = 12-13) - 80; succinic acid - up to pH 10-11; propylene glycol - the rest.